Downloads: 0
Research Paper | Medical Science | Volume 15 Issue 7, July 2026 | Pages: 897 - 899 | India
Single Donor Platelet Transfusion in Thrombocytopenic Oncology Patients: A Prospective Observational Study
Abstract: Background: Thrombocytopenia is a frequent complication among oncology patients, resulting from chemotherapy-induced bone marrow suppression, marrow infiltration by malignant cells, radiation therapy, or disease progression. Severe thrombocytopenia significantly increases the risk of bleeding and necessitates platelet transfusion. Single Donor Platelet (SDP) transfusion offers several advantages over random donor platelets by reducing donor exposure and minimizing the risk of alloimmunization and transfusion-transmitted infections. Objective: To evaluate platelet response and clinical outcomes following Single Donor Platelet transfusion in thrombocytopenic oncology patients. Materials and Methods: This prospective observational study was conducted over one year in the Department of Immunohematology and Transfusion Medicine in collaboration with the Department of Oncology, SMS Medical College and Hospital, Jaipur. Two hundred adult thrombocytopenic oncology patients receiving SDP transfusions were enrolled. Demographic characteristics, underlying malignancy, chemotherapy status, fever/sepsis, platelet refractoriness, and platelet counts before and 24 hours after transfusion were recorded and analyzed. Results: A total of 200 patients were included. The mean age was 46.8 ± 14.2 years. Male patients constituted 58.7%, while females accounted for 41.3%. Hematological malignancies comprised 64% of cases and solid malignancies 36%. Chemotherapy was administered to 80% of patients. Fever or sepsis was present in 34%, and platelet refractoriness was observed in 14%. The mean platelet count increased from 9,000 ± 3,200/μL before transfusion to 28,000 ± 8,700/μL after 24 hours, with a mean platelet increment of 19,000/μL. Patients with fever/sepsis and platelet refractoriness demonstrated comparatively lower platelet increments. Conclusion: Single Donor Platelet transfusion effectively improved platelet counts among thrombocytopenic oncology patients. Clinical factors such as infection and platelet refractoriness influenced post-transfusion platelet recovery. Larger multicentric studies are required to identify predictors of platelet response and optimize platelet transfusion practices.
Keywords: Single Donor Platelet, Thrombocytopenia, Oncology, Platelet Transfusion, Hematological Malignancy, Platelet Increment
How to Cite?: Dr. Indraj Natwadiya, Dr. Ashok Pal, Dr. Sunita Bundas, "Single Donor Platelet Transfusion in Thrombocytopenic Oncology Patients: A Prospective Observational Study", Volume 15 Issue 7, July 2026, International Journal of Science and Research (IJSR), Pages: 897-899, https://www.ijsr.net/getabstract.php?paperid=MR26710231220, DOI: https://dx.doi.org/10.21275/MR26710231220